| Offering Information |
| Expected Date | WITHDRAWN |
| Proposed Exchange/Ticker |
Nasdaq: ANAC |
| Security Type |
Common Stock |
| Lead Underwriter |
Morgan Stanley |
| Days In Registration |
480 |
| Date Filed |
31-Aug-2007 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2008) |
| Industry |
Pers/Bus/Rep Svc |
| Business Description |
Anacor Pharmaceuticals Inc, located in Palo Alto, California, is a biopharmaceutical firm engaged in the discovery, development, and production of novel drugs based on proprietary boron chemistry for the treatment of inflammatory and infectious diseases such as psoriasis, gingivitis, acne, vaginal candidiasis and tinea pedis. |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
- |
| Contact |
- |
| Number of Employees |
- |
|
| Original Filing Information |
| US |
| Shares Filed |
- |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
- |
| · As a Percent |
- |
| Overallotment Shares Filed |
- |
| File Amount |
- |
| File Price Range |
- - - |
| File Mid Price |
- |
|
